Skip to main content
Clinical Trials/NCT03888625
NCT03888625
Unknown
Not Applicable

Randomized Clinical Trials to Compare the Healing Process of Idiopathic Macular Hole With Different Surgical Techniques

Federal University of São Paulo1 site in 1 country60 target enrollmentJune 15, 2018
ConditionsMacular Holes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Macular Holes
Sponsor
Federal University of São Paulo
Enrollment
60
Locations
1
Primary Endpoint
Rate of Anatomic closure
Last Updated
7 years ago

Overview

Brief Summary

To compare anatomic and functional results, and to evaluate postoperatively the healing process in 2 different techniques for the closure of the macular holes (MH)

Detailed Description

Patients with macular holes classified in stages 3 and 4 will be randomized into 2 groups. . In Group A, patients will undergo peeling with complete removal of the internal limiting membrane (ILM) and in the group B, the inverted ILM peeling technique will be performed. The 20% sulfur hexafluoride (SF6) gas will be used as a tamponade agent in all surgeries, and patients will be instructed to avoid the prone position for 5 days. OCT images will be performed in the first 5 postoperative days and months 1, 3 and 6. The primary outcome is anatomic closure of the MH closure in the month 6. The second outcomes are: mean best corrected visual acuity (BCVA) at month 6, mean change in the BCVA at month 6; integrity of the perifoveal external limiting membrane and ellipsoid zone on Optical Coherence Tomography (OCT); MH closure rate over time in days; functional improvement of microperimetry Statistical analysis will be performed with Student t-test and the p-value of ≤ 0.05 is considered significant.

Registry
clinicaltrials.gov
Start Date
June 15, 2018
End Date
June 30, 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Federal University of São Paulo
Responsible Party
Principal Investigator
Principal Investigator

Mauricio Maia

Professor of Ophthalmology Dept

Federal University of São Paulo

Eligibility Criteria

Inclusion Criteria

  • \> Stage 3 and 4 macular holes with visual acuity between 20/30 and 20/800 according to the ETDRS chart.

Exclusion Criteria

  • Macular holes secondary to ocular trauma, myopia or retinal detachment
  • Any previous treatment for the macular hole
  • Evidence on examination of any diabetic retinopathy
  • History or presence of wet or dry age macular degeneration (AMD)
  • Presence of epiretinal membrane or prior uveitis
  • Any ocular surgery within 3 months before baseline
  • Intra or periocular infection

Outcomes

Primary Outcomes

Rate of Anatomic closure

Time Frame: Month 6 post operative

Rate of anatomic macular hole closure in the OCT at month 6

Secondary Outcomes

  • BCVA mean(Month 6 post operative)
  • BCVA change(Screening and Month 6 post operative)
  • Integrity Membrane measured in microns (μm) by OCT(Month 6 post operative)

Study Sites (1)

Loading locations...

Similar Trials